Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 2
2006 1
2008 1
2009 3
2010 2
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
[Pasteurella anatipestifer infection of water fowl].
Floren U, Wiedeking B, Kissel B, Kaleta EF. Floren U, et al. Among authors: wiedeking b. Dtsch Tierarztl Wochenschr. 1987 Nov-Dec;94(10):597-603. Dtsch Tierarztl Wochenschr. 1987. PMID: 3322779 Review. German. No abstract available.
[Pasteurella anatipestifer infection of waterfowl].
Floren U, Wiedeking B, Kissel B, Kaleta EF. Floren U, et al. Among authors: wiedeking b. Dtsch Tierarztl Wochenschr. 1987 Oct;94(9):525-34. Dtsch Tierarztl Wochenschr. 1987. PMID: 3319489 Review. German. No abstract available.
Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Wenzel RR, et al. J Am Soc Nephrol. 2009 Mar;20(3):655-64. doi: 10.1681/ASN.2008050482. Epub 2009 Jan 14. J Am Soc Nephrol. 2009. PMID: 19144760 Free PMC article. Clinical Trial.
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rössler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Alloussi S, Bock P, Strugala G, Madersbacher H. Alloussi S, et al. Among authors: wiedeking b. BJU Int. 2010 Aug;106(4):550-6. doi: 10.1111/j.1464-410X.2009.09129.x. Epub 2009 Dec 11. BJU Int. 2010. PMID: 20002668
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R. Schmermund A, et al. Among authors: wiedeking b. Circulation. 2006 Jan 24;113(3):427-37. doi: 10.1161/CIRCULATIONAHA.105.568147. Epub 2006 Jan 16. Circulation. 2006. PMID: 16415377 Clinical Trial.
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO Study Group. Lüders S, et al. J Hypertens. 2008 Jul;26(7):1487-96. doi: 10.1097/HJH.0b013e3282ff8864. J Hypertens. 2008. PMID: 18551027 Clinical Trial.